These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 31050629

  • 41. A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development.
    Idowu T, Zhanel GG, Schweizer F.
    Antimicrob Agents Chemother; 2020 Feb 21; 64(3):. PubMed ID: 31907191
    [Abstract] [Full Text] [Related]

  • 42. Ceftolozane-Tazobactam Activity against Pseudomonas aeruginosa Clinical Isolates from U.S. Hospitals: Report from the PACTS Antimicrobial Surveillance Program, 2012 to 2015.
    Shortridge D, Castanheira M, Pfaller MA, Flamm RK.
    Antimicrob Agents Chemother; 2017 Jul 21; 61(7):. PubMed ID: 28483953
    [Abstract] [Full Text] [Related]

  • 43. Carbapenem-Nonsusceptible Pseudomonas aeruginosa Isolates from Intensive Care Units in the United States: a Potential Role for New β-Lactam Combination Agents.
    Asempa TE, Nicolau DP, Kuti JL.
    J Clin Microbiol; 2019 Aug 21; 57(8):. PubMed ID: 31118271
    [Abstract] [Full Text] [Related]

  • 44. In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa.
    Tessier F, Quentin C.
    Eur J Clin Microbiol Infect Dis; 1997 Feb 21; 16(2):159-62. PubMed ID: 9105845
    [Abstract] [Full Text] [Related]

  • 45. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á, Ghazawi A, Darwish D, Barathan G, Hashmey R, Ashraf T, Rizvi TA, Pál T.
    Int J Infect Dis; 2020 Oct 21; 99():253-259. PubMed ID: 32738488
    [Abstract] [Full Text] [Related]

  • 46. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):658-663. PubMed ID: 29149337
    [Abstract] [Full Text] [Related]

  • 47. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15).
    Pfaller MA, Bassetti M, Duncan LR, Castanheira M.
    J Antimicrob Chemother; 2017 May 01; 72(5):1386-1395. PubMed ID: 28165526
    [Abstract] [Full Text] [Related]

  • 48. Poor in vitro activity of ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam against carbapenem-resistant Pseudomonas aeruginosa in India: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) program, 2018-2021.
    Lee YL, Hsueh PR.
    J Infect; 2023 Jul 01; 87(1):e1-e4. PubMed ID: 37100173
    [No Abstract] [Full Text] [Related]

  • 49. Susceptibility Profile of Ceftolozane/Tazobactam and Other Parenteral Antimicrobials Against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa From US Hospitals.
    Sutherland CA, Nicolau DP.
    Clin Ther; 2015 Jul 01; 37(7):1564-71. PubMed ID: 26088525
    [Abstract] [Full Text] [Related]

  • 50. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov 01; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 51. In vitro activity of ceftolozane-tazobactam and ceftazidime-avibactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis.
    Nolan PJ, Jain R, Cohen L, Finklea JD, Smith TT.
    Diagn Microbiol Infect Dis; 2021 Feb 01; 99(2):115204. PubMed ID: 33152675
    [Abstract] [Full Text] [Related]

  • 52. Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.
    Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Seifert H, German Carbapenem Resistance Study Group.
    Int J Antimicrob Agents; 2020 Jun 01; 55(6):105959. PubMed ID: 32325200
    [Abstract] [Full Text] [Related]

  • 53. Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.
    Hachem R, Reitzel R, Rolston K, Chaftari AM, Raad I.
    Antimicrob Agents Chemother; 2017 Apr 01; 61(4):. PubMed ID: 28115350
    [Abstract] [Full Text] [Related]

  • 54. Activity of ceftolozane-tazobactam and comparators against Pseudomonas aeruginosa from patients in different risk strata - SMART United States 2016-2017.
    Lob SH, Hoban DJ, Young K, Motyl MR, Sahm DF.
    J Glob Antimicrob Resist; 2020 Mar 01; 20():209-213. PubMed ID: 31351246
    [Abstract] [Full Text] [Related]

  • 55. Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase.
    Albiero J, Mazucheli J, Barros JPDR, Szczerepa MMDA, Nishiyama SAB, Carrara-Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB.
    Antimicrob Agents Chemother; 2019 Jun 01; 63(6):. PubMed ID: 30910903
    [Abstract] [Full Text] [Related]

  • 56. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS, Loeb M, Leto D, Brooks AA.
    Postgrad Med; 2020 Apr 01; 132(3):234-250. PubMed ID: 31608743
    [Abstract] [Full Text] [Related]

  • 57. Ceftolozane-tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Australia and New Zealand: Report from an Antimicrobial Surveillance Program (2013-2015).
    Pfaller MA, Shortridge D, Sader HS, Flamm RK, Castanheira M.
    J Glob Antimicrob Resist; 2017 Sep 01; 10():186-194. PubMed ID: 28735046
    [Abstract] [Full Text] [Related]

  • 58. Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis.
    Lasko MJ, Huse HK, Nicolau DP, Kuti JL.
    Ann Clin Microbiol Antimicrob; 2021 Jan 19; 20(1):9. PubMed ID: 33468149
    [Abstract] [Full Text] [Related]

  • 59. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
    Papp-Wallace KM, Zeiser ET, Becka SA, Park S, Wilson BM, Winkler ML, D'Souza R, Singh I, Sutton G, Fouts DE, Chen L, Kreiswirth BN, Ellis-Grosse EJ, Drusano GL, Perlin DS, Bonomo RA.
    J Infect Dis; 2019 Jul 19; 220(4):666-676. PubMed ID: 31099835
    [Abstract] [Full Text] [Related]

  • 60. In-vitro efficacy of synergistic antibiotic combinations in multidrug resistant Pseudomonas aeruginosa strains.
    Dundar D, Otkun M.
    Yonsei Med J; 2010 Jan 19; 51(1):111-6. PubMed ID: 20046523
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.